We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Physicians Perform Fewer Prostate Biopsies Post-Phi Testing

By LabMedica International staff writers
Posted on 04 Dec 2017
Prostate cancer is the third-leading cause of cancer death in men, with one in seven receiving a diagnosis during his lifetime. More...
In 2017, approximately 161,360 new cases of prostate cancer were identified, with 60% of those occurring in men 65 years of age or older.

Common methods for detecting prostate cancer include digital rectal exam (DRE) and the serum total prostate-specific antigen (PSA), followed by biopsy and transrectal ultrasound for final diagnosis. In recent years, however, the use of PSA screening for prostate cancer has come under scrutiny, with concerns that an increasing number of false-positives were leading to unnecessary invasive procedures.

Scientists collaborating with Carolina Urology Partners (Huntersville, NC, USA) carried out a prospective, observational study to determine if the use of Prostate Health Index (phi) testing changes physician behavior patterns when comparing their biopsy recommendations to a historical control group of similar patients seen by the same physicians. Patients for whom a participating urologist requested a phi test were recruited at the time of blood draw for the prospective (observational) study group. Inclusion criteria: men ≥50 years of age with total serum PSA between 4–10 ng/mL and non-suspicious DRE findings.

The Prostate Health Index (phi) (Beckman Coulter, Brea, CA, USA) is a calculation that uses a combination of three blood tests to produce a "phi score." This score provides more information about what elevated PSA levels might mean and the probability of finding prostate cancer on biopsy. The psi test comprises of three tests, PSA, free PSA, and p2PS.

The team reported that men receiving a phi test showed nearly a 24% reduction in biopsy procedures performed compared to the historical control group (36.4% versus 60.3%). Furthermore, physicians reported that the phi score significantly impacted their patient management plan in over 73% of cases, including biopsy deferrals when the phi score was low, and decisions to perform biopsies when the phi score indicated an intermediate or high probability of prostate cancer (phi≥36).

Michael Samoszuk, MD., chief medical officer, Beckman Coulter Diagnostics, said, “The phi test provides more information about the probability that a patient may have prostate cancer, giving both the patient and doctor additional insight to guide a decision as to whether a prostate biopsy is needed.” The study was published on November 20, 2017, in the journal Prostate Cancer and Prostatic Diseases.



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.